Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.96) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period in the previous year, the firm earned ($0.62) EPS. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Syndax Pharmaceuticals Trading Down 0.5 %
Shares of SNDX traded down $0.11 during mid-day trading on Thursday, hitting $21.86. The company's stock had a trading volume of 1,102,447 shares, compared to its average volume of 1,134,208. The company's 50-day moving average is $22.59 and its 200-day moving average is $19.81. Syndax Pharmaceuticals has a 52-week low of $11.22 and a 52-week high of $25.34. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -7.39 and a beta of 1.01.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on SNDX shares. StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Friday, January 19th. JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Scotiabank downgraded shares of Syndax Pharmaceuticals from a "sector outperform" rating to a "sector perform" rating and lowered their target price for the company from $36.00 to $23.00 in a research note on Wednesday, January 31st. Finally, HC Wainwright restated a "buy" rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $34.42.
View Our Latest Report on SNDX
About Syndax Pharmaceuticals
(
Get Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Further Reading
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
